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Abstract
Purpose To analyze dynamics of retinal vessel dilation
response to flicker light in patients with glaucoma and
ocular hypertension.
Patients and methods Response to flicker light was
measured in retinal vessels by means of Retinal Vessel
Analyzer. After the baseline 50 seconds long diameter
recording of inferior and superior temporal artery and vein,
three flicker stimulations of 20 seconds duration was
applied, with a 80 seconds break in between. Area under
the curve of the vessel diameter (AUC) was compared
during 3 flicker periods in the open angle glaucoma patients
group (POAG, n=47) and ocular hypertensives (OHT,
n=46) and age-matched healthy controls (n=56)
Results POAG eyes demonstrated smaller response of all
vessels to flicker light in general than the other two groups
(p=0.0008), but the response dynamics was significantly
different between the groups (p=0.038), showing in three
flicker periods a delayed increasing response in the POAG
and OHT groups, and remaining stable in healthy subjects.
Conclusion General vessel response to flicker light was
decreased in POAG patients despite the slow improvement
in repeated flicker stimulation, indicating an altered
response pattern.
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Introduction
Glaucoma is an optic neuropathy characterized by
morphologically typical changes in the optic nerve
head and accompanied by typical defects in the visual
field. Apart from intraocular pressure, blood flow
disturbances are believed to represent a major contrib-
utor to glaucomatous damage [1]. The term neuro-
vascular coupling refers to a rapid response of neural
tissue blood vessels to increased neuronal activity, and it
has recently been investigated in glaucoma patients and
patients with ocular hypertension [2, 3]. Optical accessi-
bility of the retinal vessels and the light sensitivity of the
retinal neural circuitry make the use of the Retinal Vessel
Analyzer (RVA; IMEDOS GmbH, Weimar, Germany)
particularly appealing in this field of research [4–6].
Recently, specific protocols for the use of this device have
been discussed and published [7], as well as data on
technical (measurement error) and biological (variability
of vessel response to flickering light) reproducibility [8,
9]. Neurovascular coupling makes it possible to meet an
increased perfusion demand of the neuronal tissue on a
very short time scale [10, 11]. Ischemia–reperfusion
damage is postulated as one of the important mechanisms
leading to glaucomatous optic neuropathy [12]. Increased
short-term variability of both the blood pressure and local
ocular choroidal perfusion in glaucoma patients [13]
seems to support this hypothesis. Disturbances in the
neurovascular coupling could represent an additional risk
factor for glaucoma, as they could lead to underperfusion
of retinal ganglion cells in times of critical need. We
investigated a retinal vessel response to flicker light in
untreated patients with glaucoma and ocular hyperten-
sives. In the present analysis, we focus on the dynamics
of this response to three consecutive repeated flicker-light
stimulations.
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Patients and methods
Patients
Consecutive primary open-angle glaucoma (POAG) patients
and patients with ocular hypertension (OHT) were recruited
for the study from the glaucoma consultations at the
University Eye Clinic Basel. Tenets of the Declaration of
Helsinki were followed. After approval by the ethics
committee, we obtained informed consent from our subjects.
The study was registered at ClinicalTrials.gov and the
recruitment was conducted between 2007 and 2010. Newly
diagnosed and therapy-naive POAG and OHT patients
meeting study criteria underwent study examinations; patients
on IOP-lowering therapy were first subjected to a 4-week
wash-out phase. Healthy controls were recruited through ads
in local newspapers. Subjects were screened for ocular and
systemic diseases. A detailed medical and ophthalmic history
was recorded, and all subjects completed an ophthalmological
examination, including IOP daily profiling with Goldmann
applanation tonometry (IOP readings were taken at 8 h, 11 h
and 16 h), and ultrasound pachymetry. POAG was diagnosed
based on glaucomatous optic disc cupping (in particular:
thinning of the inferior and/or superior rim, cup-to-disc ratio
asymmetry of >0.2), and based on matching glaucomatous
visual field defects [14]. Native IOP was neither exclusion
nor inclusion criterion for POAG diagnosis; hence, patients
were included from both the “high tension” and “normal
tension” side of the IOP spectrum in POAG. In contrast, at
least two daily readings of naive IOP of equal or above
21 mmHg, in absence of disc or visual field damage, were
required for the diagnosis of OHT. All participants with
diabetes mellitus, untreated or unstable essential hyperten-
sion, untreated or unstable hypercholesterolemia, drug or
alcohol abuse, history of eye surgery except pseudophakia,
high ametropia (spherical equivalent<−5 diopters or>+3
diopters), astigmatism above 2 diopters, significant cataract,
pigment or PEX dispersion syndrome, history of an acute
glaucoma attack, and any form of secondary glaucoma were
excluded from the study. Smoking was an exclusion criterion
[15]. In the POAG group, an eye with the most advanced
damage (higher mean VF defect and thinner peripapillary
RNFL as demonstrated by the optical coherence tomogra-
phy), in the OHT group an eye with the higher mean diurnal
IOP was selected, and in healthy controls one randomly
selected eye per subject entered the analysis.
Methods — retinal vessel analyzer
Details on the device and its application have been
published previously [4, 5, 7, 16]. In short, this device
consists of a fundus camera (FF450, Zeiss Jena, Germany)
for the examination and recording of the ocular fundus, and
the RVA control computer which allows continuous as well
as offline readings of the retinal vessel diameter. An
optoelectronic shutter is inserted in the fundus camera to
interrupt the observation light (530–600 nm, irradiance at
the fundus approximately 1.96×10–4 W/cm2) over the
entire 30° visual field of the retinal camera. This provides a
bright-to-dark contrast of 25:1 and at standard European
video frequency of 25 Hz produces a sequence of one
normal illuminated and one dark single frame at the
arbitrarily chosen (or more precisely said, chosen for
technical reasons) shutter frequency of 12.5 Hz of rectan-
gular light interruption. This frequency, however, does lie
in the range of the maximally exciting flicker frequency
[17, 18].
Four major temporal vessel segments, one vein and one
artery, one of each inferior and superior, was selected for
our measurements. The exact location of the measurement
was governed by the geometry of the vessel segments.
Three cycles of 20 seconds flicker light followed by
80 seconds of still illumination were conducted after an
initial, still measurement period of 50 seconds. The length
of the chosen vessel segment was again determined by the
vessel geometry, but was in all cases between 500 and 750
micrometers, which corresponds to 40 to 60 measured
diameter values (the device is set to obtain one transverse
diameter reading, based on vessel image brightness profile,
at each 12.5 micrometer vessel length). Stability of vessel
location where diameter, measured in an automated
sequence described above, is ensured by the eye/image-
tracking software, which is in turn based on the vessel
branching geometry.
Experimental procedure and data analysis
Pupil was dilated with tropicamide drops in all subjects.
After a minimum of 10–15 minutes in still seating position,
a blood pressure reading was taken, and the RVA
measurement conducted in the selected eye. RVA measure-
ments were all conducted by the same experienced
researcher (AK). For the analysis reported in this paper,
an average vessel diameter was calculated for the whole
chosen vessel segment, and its behaviour analyzed on the
time scale. Area under the curve (AUC) was calculated for
the baseline 50-second measurement, providing in fact an
average baseline diameter of the given vessel, and then the
AUC of vessel diameter during each of the 20-second-long
flicker periods (in fact, the mean vessel diameter during the
20-second flicker). The latter three values were then
expressed as a percentage change to the corresponding
baseline diameter, in other words they were standardized
with the respective baseline value. One-way repeated
measures analysis of variance was performed, one-way
(“independent”) factor being the three experimental groups,
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and “repeated” factors being: (I) the three repeated readings
under the flicker light stimulation, (II) arteries/veins, and
(III) inferior/superior temporal vessels. In essence, this was
a four-way ANOVA with one independent and three
“dependent/repeated” measures. Of particular interest was
the interaction between the factor “group” and the three
repeated measurements, with the intention to describe the
dynamics of the retinal vessel response to repeated flicker-
light stimulation in three different groups. An intraocular
pressure reading was taken immediately after the RVA
measurement.
Results
The original study goal was set at 50 subjects for each
group. In order to have a safety margin, because poor
fixators and patients with poor RVA data quality were to be
excluded, recruitment was continued in the control group
and the POAG group above this threshold. OHT patients
meeting the criteria represented a recruitment challenge,
and the recruitment was stopped as soon as the number of
50 was reached. In the ultimate analysis, however, one
OHT patient had to be excluded due to poor data quality.
All together, 59 control subjects (59±9 years of age),
55 POAG patients (60±10), and 49 OHT patients (62±9),
entered the analysis. Intraocular and blood pressure values,
as well as central corneal thickness and average baseline
vessel diameters, are presented in Table 1.
With regard to the potentially vasoactive systemic
therapy at the moment of study examinations, treatment
was as follows:
& In the POAG group: 23 patients had no therapy, six
had statines, three beta-blockers, five diuretics, seven
ACE blockers, two calcium channel blockers, five
magnesium, five aspirin, four had antidepressants
(some patients had more than one of the mentioned
medications)
& In the OHT group: 27 patients had no therapy, eight
had statines, five beta-blockers, three diuretics, three
ACE blockers, four magnesium, seven aspirin, five
had antidepressants, one had hormonal therapy
(some patients had more than one of the mentioned
medications)
& In the healthy control group: 37 patients had no
therapy, three had statines, one beta-blocker, one
diuretic, four ACE blockers, three magnesium, two
aspirin, two had antidepressants, five had hormonal
therapy (some patients had more than one of the
mentioned medications).
The Chi-square test, analyzing the number of therapy-free
patients vs patients with therapy, was between each pair of
groups not significant (smallest p=0.08).
The ANOVA model comprised the following factors:
three experimental groups (controls, POAG and OHT
patients), arteries/veins, inferior/superior temporal vessels
and AUC values (change to baseline in percentage) during
three flicker periods of 20 seconds. Results were the
following. The factor “group” had a p-value of p=0.0008
(controls 2.24±1.76 %, OHT 1.98±1.85 %, POAG 1.63±
1.57 %). Planned comparisons were made between controls
and POAG patients and they were found significantly
different (p<0.001), between OHT and POAG patients as
well (p=0.038), whereas controls and OHT patients had a
statistically comparable overall mean vessel response to
flicker (p>0.1). The factor “arteries/veins” had a p-value of
p=0.83, indicating a similar overall response of arteries and
veins (1.96% vs 1.93% respectively; reminder: values are
expressed in percentage change to average baseline value).
The factor “inferior vs superior” had a p-value of p<0.001,
indicating a stronger vessel response inferior than superior
(overall means 2.25% vs 1.65%). This difference between
Table 1 Parameters of interest at baseline, mean ± SD (units in brackets), with results of the one-way analysis of variance (ANOVA) and post-hoc
Tukey honest significant difference test between groups, where appropriate
Parameter Healthy
controls (1)
POAG
patients (2)
OHT
patients (3)
Statistics (ANOVA)
Gender (m/f) 32/27 23/2 26/23
Average retinal arterial diameter
(micrometers)
113±14 110±13 111±15 p=0.33
Average retinal venous diameter
(micrometers)
143±20 140±19 142±19 p=0.49
Naive intraocular pressure (mmHg) 13.6±2.8 16.9±4.5 21.4±4.0 p<0.001 (all post–hoc Tukey HSD test pairs
significant)
Central corneal thickness
(micrometers)
545±38 539±51 562±37 p<0.001 (in post–hoc Tukey HSD test, OHT different
to the other two)
Systolic blood pressure (mmHg) 141±22 134±19 147±26 p=0.07
Diastolic blood pressure (mmHg) 81±12 76±11 80±13 p=0.06
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inferior and superior temporal retinal segments was
comparably present in arteries and veins (interaction
between factors “arteries/veins” and “inferior/superior”
was p=0.53).
With all groups taken together, the fourth factor (three
repeated flicker stimulations) demonstrated a p-value of p=
0.02, with overall response means of 1.8% vs 2.0% vs 2.1%.
When, however, the groups were analyzed separately in this
regard, by means of interaction between the factor “group”
and the factor “repeated flicker measurements”, p-value was
p=0.04, indicating a response increase in subsequent flicker
stimulation in the OHT and POAG group (no significant
difference between the two, planned comparisons, p=0.61),
as opposed to constant and stable vessel response in the
control group throughout three flicker periods (planned
comparisons, POAG vs controls p=0.03, OHT vs controls
p=0.007).
Figure 1 represents the AUC in three groups during three
flicker periods; inferior and superior, as well as arteries and
veins, are collapsed together in order to graphically depict
the main finding of this analysis — differences in the
dynamics of the vessel response across groups.
Discussion
In the present study, we focus on the results of the
dynamics analysis of the retinal vessel response to repeated
light stimulation in POAG and OHT patients and age-
matched controls. On average, all retinal vessels of the
POAG patients, arteries as well as veins, demonstrated a
diminished response to flicker light stimulation. This mean
response was clearly smaller than in controls, and border-
line smaller than in OHT patients. There was no significant
difference in the mean vessel response between the OHT
patients and controls; however, the dynamics of this
response during three flicker periods was different. The
response dynamics was comparable between the OHT and
the POAG group, and both demonstrated significantly
different behaviour of the response compared to controls.
Garhofer et al. [2] found significantly diminished retinal
vein response to flickering light in patients with early
glaucoma compared with healthy volunteers. Results of the
present study are similar, except arteries seem to demonstrate
an altered response as well. Direct comparison of the vessel
response dynamics with the above study is not possible, as a
different flicker protocol was used.
Based on the present data, it remains an open question
whether generally diminished response of all retinal vessel
in POAG patients is a cause or a consequence of the
glaucomatous damage. If the former, a vascular dysregula-
tion compromising the neurovascular coupling response
might be present in glaucoma patients, and might have
contributed to the glaucomatous damage [6]. If the latter,
less tissue, as a result of glaucomatous damage, could mean
less perfusion demand, and hence on the average smaller
retinal vasodilation — in contrast to OHT patients, the
vessel response level of the POAG remained below that of
controls in all three flicker repetitions.
In contrast to controls, where the vessel response was
stable throughout the examination, in OHT and POAG
patients the response seems to increase with time, with each
next flicker period, indicating a slower adjustment of the
vessel regulatory mechanisms to the increased tissue
perfusion demand. This “conditioning” of the vessel
response was not present in controls; the response was
constant in all three flicker periods. The similarity of the
behaviour pattern between the POAG patients and the
OHTs could indicate a role of increased intraocular pressure
in the process; both groups had a native IOP significantly
higher than the controls. However, in the OHT group the
vessel response did reach the level observed in controls in
the third flicker period, and also as mentioned above there
was no significant difference in mean response between the
OHTs and controls. On the other hand, our cohort of POAG
patients had significantly lower native IOP level than the
OHT group. Being a tertiary referral centre specialized in
ocular vascular disorders, it is likely that our cohort of
POAG patients there is shifted towards “normal”-tension
glaucoma patients, and that mechanisms other than IOP
might have played a role. One possibility is that dysregu-
lation of endothelium-derived substances, whose function is
altered in normal-tension glaucoma [19, 20], also affects the
0,0
0,5
1,0
1,5
2,0
2,5
3,0
Controls POAG OHT
Combined vessel response 
(AUC standardized with 
baseline,expressed in %)
1. flicker stimulation
2. flicker stimulation
3. flicker stimulation
Fig. 1 All measured retinal vessels (arteries and veins, inferior and
superior temporal vessels) pooled together. Depicted parameter (mean
± SE) is the area under the curve (AUC) during each 20 seconds of
flicker stimulation, standardized with baseline vessel diameter level.
AUC is in fact the mean vessel diameter during the 20 seconds of
flicker stimulation; this value was expressed as change to baseline in
percentages (%) of baseline, and hence represents a mean vessel
diameter increase during the flicker stimulation. Significant differ-
ences of this parameter across groups and the three flicker periods are
reported in detail in the text of the Results section
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neurovascular coupling. Failing to provide adequate perfu-
sion in times of increased need may lead to short-term
ischemia and hence to reperfusion damage [12]. The
response “conditioning”, an increase of response with each
next flicker period, might represent an attempt, even though
insufficient, of regulatory mechanisms to meet an increased
tissue demand.
In the study from 2006 [16], the retinal vessel response
dynamics was analyzed in healthy vasospastic and non-
vasospastic subjects, and the non-vasospastic group dem-
onstrated a response augmentation in three flicker periods.
There are, however, important differences to the present
study cohort and design: neither controls nor the patients
were subdivided according to their vasospastic propensity,
the grouping criteria here was solely the presence of the
disease. More importantly, the former study analysed the 1-
second vasodilation of the vessels with the goal of
capturing the maximal vessel diameter excursion in young
healthy subjects. In the present study, an AUC was
calculated for three flicker stimulations, thus containing
information about the vessel behaviour throughout each
entire 20-second flicker period.
An additional weakness of the study is that the RVA
device measures the thickness of the blood column and not
directly the diameter of the vessels, as they are optically
invisible. However, the blood column thickness, and
especially its changes, can be viewed as a reliable indicator
of the vessel diameter.
The circulation of interest in glaucoma is the choroidal
circulation and not the retinal vasculature, apart from the
superficial layer of the optic disc tissue. Blood supply from
the short-posterior arteries is more relevant to explain the
vascular component of glaucoma damage than the temporal
retinal arteries, limiting the value of the present findings. It
is nevertheless interesting that the neighbouring vascular
bed demonstrates such flow alterations, re-affirming the
hypothesis that an underlying vascular dysregulation is
involved in the pathogenesis of glaucoma.
Systemic medications may have influenced some
aspects of ocular blood flow measurements; however,
the drug distribution was comparable across groups. The
number of patients taking individual drugs, or drug
groups, was too small for a meaningful subanalysis.
However, as no patient preselection was made based on
systemic medication, the composition of the present
patient cohorts probably reflects an average composition
of patients in the daily practice.
In conclusion, retinal vascular response of untreated
POAG patients to repeated flicker light stimulation is both
reduced and demonstrates an altered pattern compared to
age-matched controls. Future research is required to
examine possible diagnostic and therapeutic consequences
of this finding.
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